Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells

Autor: Margot S.F. Roeten, Johan van Meerloo, Zinia J. Kwidama, Giovanna ter Huizen, Wouter H. Segerink, Sonja Zweegman, Gertjan J.L. Kaspers, Gerrit Jansen, Jacqueline Cloos

Publikováno v: Cells, Vol 10, Iss 3, p 665 (2021)

At present, 20–30% of children with acute leukemia still relapse from current chemotherapy protocols, underscoring the unmet need for new treatment options, such as proteasome inhibition. Ixazomib (IXA) is an orally available proteasome inhibitor,

Externí odkaz: https://doaj.org/article/d4a7babdfc8741c2a36eeee2b88bbbb5

Periplocin Overcomes Bortezomib Resistance by Suppressing the Growth and Down-Regulation of Cell Adhesion Molecules in Multiple Myeloma

Autor: Abdul Aziz, Haiqin Wang, Yanpeng Wang, Zhenzhen Li, Chaoying Yang, Zekang Ma, Xiaojuan Xiao, Jing Liu

Publikováno v: Cancers
Volume 15
Issue 5
Pages: 1526

Multiple myeloma (MM) is an incurable hematological malignant disorder of bone marrow. Patients with MM receive multiple lines of chemotherapeutic treatments which often develop bortezomib (BTZ) resistance and relapse. Therefore, it is crucial to ide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d38ebda7739c0d1396d90c5a6c94555
https://doi.org/10.3390/cancers15051526

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells

Autor: Gertjan J.L. Kaspers, Sonja Zweegman, Johan van Meerloo, Zinia J. Kwidama, Giovanna ter Huizen, Gerrit Jansen, Jacqueline Cloos, Margot S. F. Roeten, Wouter H. Segerink

Publikováno v: Roeten, M S F, van Meerloo, J, Kwidama, Z J, ter Huizen, G, Segerink, W H, Zweegman, S, Kaspers, G J L, Jansen, G & Cloos, J 2021, ' Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells ', Cells, vol. 10, no. 3, 665, pp. 1-15 . https://doi.org/10.3390/cells10030665
Cells
Volume 10
Issue 3
Cells, 10(3):665, 1-15. MDPI Multidisciplinary Digital Publishing Institute
Cells, Vol 10, Iss 665, p 665 (2021)

At present, 20–30% of children with acute leukemia still relapse from current chemotherapy protocols, underscoring the unmet need for new treatment options, such as proteasome inhibition. Ixazomib (IXA) is an orally available proteasome inhibitor,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2b163b89de767ad688c208c8b46df8a
https://research.vumc.nl/en/publications/9792b04a-da28-4ed2-81d5-a33315fdef31

Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma

Autor: Gonzalez-Santamarta, M, Quinet, G, Reyes-Garau, D, Sola, B, Roue, G, Rodriguez, MS

Publikováno v: Advances in Experimental Medicine and Biology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Since its introduction in the clinics in early 2000s, the proteasome inhibitor bortezomib (BTZ) significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell lymphoma (MCL), two of the most challenging B cell malignancie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::0f0688d80ab3e9b4ef51f25ba177d66b
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4738

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.